Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
26 November 2024 | Story Leonie Bolleurs | Photo Supplied
SARIMA presentations 2024
The UFS DRD team that attended and presented at the 2024 SARIMA conference in Maputo, Mozambique.

The Directorate Research Development (DRD) team from the University of the Free State (UFS) joined research management professionals from across the globe at the 2024 Southern African Research and Innovation Management Association (SARIMA) Conference held in September this year. This year's conference, hosted for the first time in Mozambique, focused on the theme, It Takes a Village to Raise a Child, highlighting the collective effort needed in research and innovation.

The UFS delegation participated in workshops on navigating change, unlocking research impact potential, tools and techniques for research and innovation project management, reviewing research-related contracts, and assessing associated risks. The Bill and Melinda Gates Foundation also led a training session, while other workshops explored strengthening global research partnerships and advancing competencies in research management.

Opportunity to share and learn about best practices

Boemo Segoje, Officer for RIMS, Ethics and Creative Outputs, reflected on the conference’s collaborative atmosphere, noting the opportunity to share and learn about best practices. Segoje, alongside Maricel van Rooyen, Senior Officer: Project Manager, RIMS and Ethics, presented a poster titled, Empower the Village with an Effective Research Management System, showcasing the university’s InfoEd Research Information Management System (RIMS). “Our audience was particularly impressed with how RIMS consolidates various research functions into one platform,” said Segoje.

Another UFS poster by Mpho Mashamba, Officer: RIMS Development and Maintenance, and Ethics and Katleho Nyaile from the Centre for Graduate Support (CGS) focused on Breaking Down Silos: Enhancing Interdepartmental Communication in Research Administration. They highlighted the need for collaboration within the university, emphasising how interdepartmental communication enhances research outcomes. “We referred to the importance of collaborating with other units, keeping a line of communication open, as well as engaging various stakeholders. This is especially important for a team like ours whose work impacts every faculty member,” said Mashamba.

Mandy Jampies, Senior Officer Postdoctoral Fellows presented on It Takes a Village: Fostering Collaborative Networks for Postdoctoral Fellow Management. This talk focused on building a ‘village’ for postdoctoral fellows by streamlining visa processes and establishing partnerships with other institutions, such as the University of Johannesburg. "The audience showed great interest in our initiatives, particularly the visa partnership with the Department of Home Affairs," Jampies remarked.

Jampies’s commitment to supporting postdoctoral fellows extended beyond her presentation. In addition to discussing ways to build a supportive ‘village’ through streamlined visa processes and collaborative partnerships, she also played a role in the science communication pre-conference workshop. Reflecting on this workshop, Jampies noted it as a standout moment. “Boemo Segoje and I had the chance to present on the university’s initiatives to boost research visibility through newsletters, social media and webinars,” she shared.

Sugan Moodley, Director of Research Development Finance, remarked that it was interesting to see the Research Management progression made by universities and to compare similarities, differences, strengths and weaknesses between the UFS and other universities.

AI, here to stay

Mashamba found inspiration in a session by the University of Ghana, where he drew parallels between Ghana’s research fund and the UFS Central Research Fund. “Learning from their experience will help enhance our processes here at the university,” he shared. A big fan of lifelong learning, he saw the conference as a great opportunity to pick up new ideas. He said, "I really made the most of every moment. For me, a few key things stood out. First off, having clear policies and standard operating procedures (SOPs) is important for making things run smoothly and getting more done.”

He continued, “As for AI, it’s definitely here to stay. I’m excited about the potential AI has to help streamline our work. Once it’s ready to be used effectively in the workplace, I’d love to bring it into our systems and even use it to improve what we’re already doing." Additionally, Dr Glen Taylor, the Director of Research Development at the UFS, expressed similar enthusiasm for the AI presentation, finding it an interesting insight into the future of research processes.

For Segoje, the conference also highlighted the importance of leadership in research management, referring to a session by the University of Pretoria on Ubuntu leadership. “The emphasis on Ubuntu aligns with the UFS’s values, emphasising the importance of sharing knowledge and empowering others,” she said.

Reflecting on the conference, Jampies concluded, “SARIMA 2024 was one of the best conferences I have attended, providing a wealth of practical knowledge that I can apply to improve my work portfolio.”

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept